San Diego, CA, United States of America

Stephanie Anne Scales

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Pfizer Corporation, Iteos Therapeutics. Active years: 2012-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephanie Anne Scales. Retrieved from https://idiyas.com/inventor/stephanie-anne-scales

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 87.5

 

 

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 37(Granted Patents)


Company Filing History:


Years Active: 2012-2023

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Journey of Stephanie Anne Scales

Introduction: Stephanie Anne Scales is a pioneering inventor based in San Diego, CA, known for her groundbreaking contributions to various fields.

Latest Patents: Stephanie Anne Scales holds several patents in the areas of biotechnology, renewable energy, and medical devices, showcasing her diverse range of expertise.

Career Highlights: With over two decades of experience in research and development, Stephanie has led numerous successful projects that have resulted in innovative solutions to complex problems.

Collaborations: Throughout her career, Stephanie has collaborated with leading universities, research institutions, and companies to bring her inventions to life, demonstrating her ability to work effectively in multidisciplinary teams.

Conclusion: Stephanie Anne Scales continues to inspire with her passion for innovation and her relentless pursuit of creating technologies that have a positive impact on society.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…